Absci Corporation

NASDAQ:ABSI

Biotechnology

Healthcare
$8.18 +1.04%

+$0.08 today

Market cap
$1.41B
Beta
2.46
P/E (TTM)
-9.4
EPS (TTM)
-$0.77
52W Low $2.24High $8.17

Volume 5.66M

Average 5.10M

ABSI Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Absci CorporationNASDAQ: ABSI

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 152.96M shares rose 22.9% year over year, in line with the +23.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.6% from the prior quarter. Over 3 fiscal years it compounded at +14.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +22.9% toward the trailing-twelve-month pace of +23.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
152.96M+1.6% QoQ
Last fiscal yearDec 2025
136.78M+24.1% YoY
LTMMar 2026
143.73M+23.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.9%——
1 year+24.1%——
3-year CAGR+14.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
136.78M USD
Year-over-year change
+24.1%
4-year CAGR
+10.2%

Weighted Avg Shares vs competitors

How ABSI compares with its peers on the latest reported figures

  • ABSI's LTM Mar 2026 weighted avg shares of 143.73M shares is the 2nd highest of the 3 companies compared; the peer median is 178.22M shares.
  • Its year-over-year change of +23.4% is the highest of 3, against a peer median of -28.8%.
  • Over three fiscal years its annual growth of +14.6% compares with a peer median of +1.6%.
ABSI Competitors Peer median
Weighted Avg Shares for ABSI and competitors
Company Period LTM YoY 3-year CAGR
ABCLAbCellera Biologics Inc.LTM Sep 2026306.35M +3.0%+1.6%
ABSIAbsci CorporationLTM Mar 2026143.73M +23.4%+14.6%
GENBGenerate Biomedicines, Inc.FY202550.09M -60.7%—
Peer median (excluding ABSI) 178.22M-28.8%+1.6%

Competitors are the stored peer set for ABSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.78M5.75M5.72M4.53M2.8M
Cost of Revenue44.59M58.91M47.57M62.46M11.74M
Gross Profit(39.8M)(53.16M)(41.85M)(57.93M)(8.94M)
Gross Margin-832.4%-925.0%-731.9%-1277.6%-319.4%
Research & Development44.59M58.91M48.07M63.86M81.42M
Selling, General & Admin000035.06M
Operating Expenses35.43M53.59M73.67M50.96M115.78M
Depreciation & Amortization6.65M13.04M14M13.39M11.74M
EBITDA(67.68M)(91.36M)(79.68M)(94.1M)(103.16M)
EBITDA Margin-1415.4%-1589.6%-1393.5%-2075.4%-3684.4%
Operating Income(75.24M)(106.75M)(115.52M)(108.89M)(124.72M)
Operating Margin-1573.4%-1857.5%-2020.2%-2401.6%-4454.2%
Interest Income00000
Interest Expense3.43M972K1.01M565K209K
Other Income / Expenses(34.62M)1.39M5.05M5.85M9.6M
Income Before Tax(109.86M)(105.37M)(110.47M)(103.04M)(115.11M)
Pre-Tax Margin-2297.3%-1833.4%-1931.9%-2272.5%-4111.2%
Income Tax Expense(8.9M)(461K)100K70K69K
Net Income(100.96M)(104.9M)(110.57M)(103.11M)(115.18M)
Net Margin-2111.3%-1825.4%-1933.6%-2274.1%-4113.7%
EPS (Basic)(1.11)(1.15)(1.20)(0.94)(0.84)
EPS (Diluted)(1.11)(1.15)(1.20)(0.94)(0.84)
Weighted Avg Shares92.65M90.85M92.03M110.24M136.78M
Weighted Avg Shares (Diluted)92.65M90.85M92.03M110.24M136.78M

Absci Corporation

NASDAQ:ABSI

Intrinsic Alpha fair value

Locked

Current Price

$8.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.